Jazz secures FDA approval for Ziihera in advanced HER2+ GEA
Pharmaceutical Technology
The FDA has approved two Jazz Pharmaceuticals regimens containing Ziihera for the first-line treatment of adults with unresectable, locally advanced or metastatic HER2-positive GEA.
pharminent
August 26, 2026 (Last updated: August 26, 2026)
Pharmaceutical Technology
The FDA has approved two Jazz Pharmaceuticals regimens containing Ziihera for the first-line treatment of adults with unresectable, locally advanced or metastatic HER2-positive GEA.
